Liver involvement and mortality in COVID-19: A retrospective analysis from the CORACLE study group.
Infez Med
; 30(1): 80-85, 2022.
Article
in English
| MEDLINE | ID: covidwho-1772291
ABSTRACT
Introduction:
liver abnormalities are common in COVID-19 patients and associated with higher morbidity and mortality. We aimed to investigate clinical significance and effect on the mortality of abnormal liver function tests (ALFTs) in COVID-19 patients.Methods:
we retrospectively evaluated in a multicentre study all patients admitted with confirmed diagnosis of COVID-19.Results:
434 patients were included in this analysis. Among overall patients, 311 (71.6%) had normal baseline ALT levels. 123 patients showed overall abnormal liver function tests (ALFTs) at baseline [101 ALFTs <2x UNL and 22 ≥2 UNL]. Overall in-hospital mortality was 14% and mean duration of hospitalization was 10.5 days. Hypertension (50.5%), cardiovascular diseases (39.6%), diabetes (23%) were frequent comorbidities and 53.7% of patients had ARDS. At multivariate analysis, the presence of ARDS at baseline (OR=6.11; 95% CI 3.03-12.32; p<0.000); cardiovascular diseases (OR=4; 95% CI 2.05-7.81; p<0.000); dementia (OR=3.93; 95%CI1.87-8.26; p<0.000) and no smoking (OR=4.6; 95% CI 1.45-14.61; p=0.010) resulted significantly predictive of in-hospital mortality. The presence of ALFTs at baseline was not significantly associated with mortality (OR=3.44; 95% CI=0.81-14.58; p=0.094).Conclusion:
ALFTs was frequently observed in COVID-19 patients, but the overall in-hospital mortality was mainly determined by the severity of illness, comorbidities and presence of ARDS.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Language:
English
Journal:
Infez Med
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Affiliation country:
Liim-3001-9
Similar
MEDLINE
...
LILACS
LIS